Mineralocorticoid receptor antagonists in the treatment of patients with chronic heart failure. Positions in 2015

被引：0
|
作者：
Osmolovskaya, Yu. F. [1 ]
Zhirov, I. V. [1 ]
Tereshchenko, S. N. [1 ]
机构：
[1] Minist Hlth Russia, AL Myasnikov Inst Clin Cardiol, Dept Myocardial Dis & Heart Failure, Russian Cardiol Res & Prod Complex, Moscow, Russia
来源：
TERAPEVTICHESKII ARKHIV | 2015年 / 87卷 / 09期
关键词：
aldosterone; mineralocorticoid receptor antagonists; chronic heart failure; PRESERVED EJECTION FRACTION; CHRONIC KIDNEY-DISEASE; SELECTIVE ALDOSTERONE BLOCKER; MILD PATIENTS HOSPITALIZATION; DOUBLE-BLIND; BAY; 94-8862; MYOCARDIAL-INFARCTION; EUROPEAN-SOCIETY; ASSOCIATION HFA; EMPHASIS-HF;
D O I：
10.17116/terarkh201587977-83
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Mineralocorticoid receptor antagonists (MCRA) are part of standard medical therapy for heart failure (HF). The clinical efficacy of MCRA in patients with systolic HF has been proven by randomized clinical trials. The efficacy of this drug group in patients with chronic HF with preserved left ventricular systolic function and the advent and practical introductions of safer new-generation MCRA remain to be answered.
引用
收藏
页码：77 / 83
页数：7
相关论文
共 50 条
  • [31] New mineralocorticoid receptor antagonists: update on their use in chronic kidney disease and heart failure
    Capelli, Irene
    Gasperoni, Lorenzo
    Ruggeri, Marco
    Donati, Gabriele
    Baraldi, Olga
    Sorrenti, Giovanni
    Caletti, Maria Turchese
    Aiello, Valeria
    Cianciolo, Giuseppe
    La Manna, Gaetano
    JOURNAL OF NEPHROLOGY, 2020, 33 (01) : 37 - 48
  • [32] Vasopressin receptor antagonists in patients with chronic heart failure
    De Vecchis, R.
    Cantatrione, C.
    Mazzei, D.
    HERZ, 2017, 42 (05) : 492 - 497
  • [33] The prognostic value of plasma galectin-3 in chronic heart failure patients treated with mineralocorticoid receptor antagonists
    Rouet, P.
    Koukoui, F.
    Desmoulin, F.
    Barutaut, M.
    Caubere, C.
    Berry, M.
    Evaristi, M.
    Smih, F.
    Galinier, M.
    EUROPEAN HEART JOURNAL, 2014, 35 : 673 - 673
  • [34] HYPERKALEMIA IS THE MAIN CAUSE OF MINERALOCORTICOID RECEPTOR ANTAGONISTS WITHDRAWAL AND IS ASSOCIATE WITH A WORSE PROGNOSIS IN PATIENTS WITH CHRONIC HEART FAILURE
    Lisi, F.
    Grande, D.
    Parisi, G.
    Gioia, M.
    Amato, L.
    Bellino, M.
    Ciccone, M.
    Caldarola, P.
    Iacoviello, M.
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2019, 21 (0E) : E230 - E231
  • [35] Mineralocorticoid Receptor Antagonists in High-Risk Heart Failure Patients With Diabetes Mellitus and/or Chronic Kidney Disease
    Pitt, Bertram
    Rossignol, Patrick
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2017, 6 (12):
  • [36] The role of mineralocorticoid receptor antagonists in the treatment of cardiac failure
    Funder, JW
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2003, 12 (12) : 1963 - 1969
  • [37] Obesity-Associated Heart Failure as a Theoretical Target for Treatment With Mineralocorticoid Receptor Antagonists
    Packer, Milton
    JAMA CARDIOLOGY, 2018, 3 (09) : 883 - 887
  • [38] Non-steroidal mineralocorticoid receptor antagonists in heart failure
    Filippatos, Gerasimos
    Farmakis, Dimitrios
    NATURE REVIEWS CARDIOLOGY, 2023,
  • [39] Effects of steroidal mineralocorticoid receptor antagonists on acute and chronic estimated glomerular filtration rate slopes in patients with chronic heart failure
    Vaduganathan, M. Muthiah
    Ferreira, J. P.
    Rossignol, P.
    Neuen, B.
    Claggett, B. L.
    Pfeffer, M. A.
    Mcmurray, J. J. V.
    Pitt, B.
    Zannad, F.
    Solomon, S. D.
    EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 : 135 - 136
  • [40] Hyperkalaemia as a cause of undertreatment with mineralocorticoid receptor antagonists in heart failure
    Henrysson, Josefin
    Thunstrom, Erik
    Chen, Xiaojing
    Fu, Michael
    Basic, Carmen
    ESC HEART FAILURE, 2023, 10 (01): : 66 - 79
12345